Some smokers may pay higher premiums for health insurance under the Affordable Care Act. In an interview on Kaiser Health News, Michelle Andrews discusses how the health law will affect insurance for smokers, and programs that may help them quit:
The provisions that allow insurers to charge smokers higher premiums take effect in January and apply to health plans sold on the individual and small group markets that aren't grandfathered under the law. The insurer may well rely on people to self-report their tobacco use, asking them, for example, if they've used tobacco regularly in the past six months. You're apparently concerned that people won't disclose that they're smokers, and some may not. But it's important to remember that research shows that most smokers want to quit, and under the health law people won't be penalized as long as they're trying to do so, even if they don't succeed. If a company has a wellness program that offers a tobacco cessation program and if smokers participate in it, they're not going to have to pay the higher rate. Participation is enough, workers don't have to actually succeed at quitting, which often takes several tries. So that may encourage people to 'fess up to their smoking habit.
Read the full story here: http://bit.ly/1a7eWRY
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
2 Commerce Drive
Cranbury, NJ 08512